论文部分内容阅读
动物实验证明：乙肝转阴汤Ⅰ、Ⅱ、Ⅲ对SD小鼠CCL4中毒性肝炎有保护肝细胞的作用，与对照组比较P＜0．05有显著性差异。临床应用乙肝转阴汤Ⅰ、Ⅱ、Ⅲ号治疗慢性乙型肝炎90例，分3组，每组30例。Ⅰ号方用于肝郁脾虚证，Ⅱ方用于湿热中阻证，Ⅲ号方用于血瘀阻络证，对照组30例应用人白细胞干扰素。结果：乙肝病毒标志物（HBV—M）变化：HBeAg、抗HBc—Igm、HBV—DNA转阴率：Ⅰ号方组为50％43．3％、46．2％；Ⅱ号方组60％、50％、48．1％：Ⅲ号方组53．3％、53．3％、44．4％；对照组26．6％、20％、19．2％，经X2检验，除Ⅰ号方组HBeAg、抗HBeIgm转阴率与对照组比较P＞0．05外，Ⅱ、Ⅲ号方组均P＜0．05有显著性差异。有效率：Ⅰ、Ⅱ、Ⅲ号及对照组分别为63．3％、76.7％、70％、33．3％，经X2检验P＜0．05有显著性差异。结论：乙肝转阴汤Ⅰ、Ⅱ、Ⅲ号对慢性乙型肝炎有使HBV—M中复制指标转阴作用，并有较好的降酶、退黄改善肝功能作用。
Animal experiments show that: Yigan Zhuanyin Decoction I, II, and III can protect hepatocytes from CCL4 toxic hepatitis in SD mice, and there is a significant difference (P<0.05) from the control group. The clinical application of hepatitis B Zhuanying Decoction I, II, III No. 90 cases of chronic hepatitis B, divided into 3 groups, 30 cases in each group. No. I prescription was used for deficiency of liver and spleen deficiency, II prescription was used for dampness and heat resistance, III prescription was used for blocking blood stasis, and control group was treated with human leukocyte interferon 30. Results: Changes of HBV marker (HBV-M): HBeAg, anti-HBc-Igm, HBV-DNA negative rate: 50% 43.3%, 46.2% in group I; 60% in group II , 50%, 48.1%: 53.3%, 53.3%, 44.4% for group III; 26.6%, 20%, and 19.2% for control group, after X2 test, except I The HBeAg and anti-HBeIgm negative rate in the group was higher than that in the control group (P>0.05), and there was a significant difference in P<0.05 in the groups II and III. Effectiveness: I, II, III and control groups were 63.3%, 76.7%, 70%, and 33.3%, respectively, and there was a significant difference by X2 test P<0.05. Conclusion: Yigan Zhuanyin Decoction I, II, and III can reverse the duplication of HBV-M in chronic hepatitis B, and have a good effect of lowering enzyme and yellowing to improve liver function.